Financial terms of the agreement were not disclosed.
This is a transformative step for the company and will broaden its immunomodulation platform into oncology.
The licensed technology is a modified measles virus based on the viral genome sequence of the established measles vaccine strain, which has been used to immunize billions of people worldwide.
The measles virus itself has innate anti-cancer properties, for example, mediating tumor cell lysis, T cell activation and specific tumor cell targeting.
Furthermore, it can also be engineered to include a tumor killing payload, making it a major building block for an effective oncolytic virus immunotherapy.
Themis established a cGMP manufacturing process for its measles vector technology and built a broad pipeline with both proprietary and partnered infectious disease vaccine candidates.
The lead programme in Chikungunya is anticipated to enter Phase 3 development in the near- to medium-term.
Themis believes that this licensing deal with Max-Planck-Innovation GmbH will further expand its innovative technology platform to include novel oncolytic virus-based immunotherapy applications.
Themis is developing immunomodulation therapies for infectious diseases and cancer.
As a technology transfer organisation of the Max Planck Society, Max Planck Innovation is the link between industry and basic research.
Its interdisciplinary team provides consulting and support for scientists in evaluating inventions, applying for patents, and founding companies. 134 spin-off companies have emerged from the Max Planck Society, of which the majority was accompanied by Max-Planck-Innovation.
Founded in 1805, the University Hospital Tuebingen is one of the leading centres of German university medicine.
As one of 33 University Hospitals in Germany, it contributes to a combination of medicine, research, and teaching.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study